

Face Page:

Title: Chemotherapy induced peripheral neuropathy increases non-traumatic fracture risk in breast cancer survivors

Running title: Chemotherapy neuropathy increases fragility fracture (5-word max)

Brendan L. McNeish MD¹, James K. Richardson MD¹, Sarah G. Bell MD², Daniel G. Whitney PhD^{1,3}

1. Department of Physical Medicine and Rehabilitation
Michigan Medicine
Ann Arbor, MI, USA
2. Department of Obstetrics and Gynecology
University of Michigan,
Ann Arbor, MI, USA
3. Institute for Healthcare Policy and Innovation
University of Michigan,
Ann Arbor, MI, USA

Brendan L. McNeish is the corresponding author, mcneishb@med.umich.edu

ORCID:

BLM: <https://orcid.org/0000-0002-8285-168X>

JKR: <https://orcid.org/0000-0002-9426-196X>

SGB: <https://orcid.org/0000-0002-9455-5108>

DGW: <https://orcid.org/0000-0003-2132-1527>

The authors did not receive support from any organization nor having conflicts of interests for the submitted work.

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Brendan L. McNeish and Daniel G. Whitney. The first draft of the manuscript was written by Brendan L. McNeish and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: [10.1002/jbm4.10519](https://doi.org/10.1002/jbm4.10519)

This article is protected by copyright. All rights reserved.

Disclosure Page:

Funding: DGW receives funding through the University of Michigan Office of Health Equity and Inclusion Diversity Fund and the American Academy for Cerebral Palsy and Developmental Medicine. The authors JKR, SGB & BLM did not receive support from any organization for the submitted work.

COI: All authors deny having conflicts of interest for the submitted work.

Availability of data: The data that support the findings of this study are available from Optum's De-identified Clinformatics® Data Mart Database (OptumInsight™, Eden Prairie, MN, USA) but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of Optum's De-identified Clinformatics® Data Mart Database (OptumInsight™, Eden Prairie, MN, USA).

Availability of code: Data are available from the authors upon reasonable request.

Author Contributions: All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Brendan L. McNeish and Daniel G. Whitney. The first draft of the manuscript was written by Brendan L. McNeish and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Abstract

Chemotherapy is a common treatment for breast cancer (BrCa) and can cause chemotherapy induced peripheral neuropathy (CIPN). CIPN contributes to falls, and is thus a potential risk factor for non-traumatic fractures (NTFx); yet, the effect of CIPN on NTFx risk has not been examined for BrCa survivors. We therefore investigated the association between CIPN and NTFx in BrCa survivors. Data were extracted from Optum's De-identified Clinformatics® Data Mart Database years 2010-2015 in this retrospective cohort study. Among women, three groups were derived based on BrCa and CIPN status: BrCa+/CIPN+ (primary group of interest), BrCa+/CIPN- (first comparison group), and BrCa-/CIPN- (second comparison group). After propensity score matching the comparison groups to BrCa+/CIPN+ at a ratio of 1:11 (BrCa:control) for demographics, osteoporosis, glucocorticoid medication, comorbidities, and cancer-related variables for BrCa+/CIPN-, one-year incidence rate (IR) of NTFx was determined

for each group. The incident rate ratio (IRR) determined if the IR for NTFx was different for BrCa+/CIPN+ compared to BrCa+/CIPN- and BrCa-/CIPN-. Cox proportional hazards regression models estimated the hazard ratios (HR) after adjusting for covariates that were unable to be matched for. The crude IR (95%CI) of NTFx was 4.54 (2.32-6.77) for BrCa+/CIPN+ (n=359), 2.53 (2.03-3.04) for BrCa+/CIPN- (n=3,949), and 1.76 (1.35-2.18) for BrCa-/CIPN- (n=3,949). The crude IRR of NTFx was significantly elevated for BrCa+/CIPN+ as compared to BrCa+/CIPN- (IRR=1.80; 95%CI=1.06-3.05) and BrCa-/CIPN- (IRR=2.58; 95%CI=1.50-4.44). The elevated rate of NTFx for BrCa+/CIPN+ remained unchanged after adjusting for aromatase inhibitors compared to BrCa+/CIPN- (HR=1.79; 95%CI=1.06-3.04). Female BrCa survivors have an increased one-year IR of NTFx after the onset of CIPN, suggesting that CIPN is an additive burden on NTFx risk among BrCa survivors.

Keywords: Tumor induced bone disease; Osteoporosis; fracture prevention; fracture risk assessment; cancer

Title: Chemotherapy induced peripheral neuropathy increases non-traumatic fracture risk in breast cancer survivors

As of 2019, breast cancer (BrCa) survivors total 3.9 million and life expectancy continues to increase due to improvements in early detection and effective cancer treatments.⁽¹⁾ BrCa treatments such as chemotherapy, radiation, and particularly endocrine therapy have been associated with bone loss, increasing the risk for non-trauma fracture (NTFx), an indicator for bone fragility.^(2,3) Importantly, NTFx may lead to higher risk of hospitalization and death in this population.⁽⁴⁾ The burden of NTFx among BrCa survivors underscores the importance of identifying and treating those most at risk for NTFx and the associated morbidity and mortality.

A common course of treatment for BrCa survivors is chemotherapy, often including neurotoxic agents such as taxanes, which are known to disrupt the function of the peripheral nervous system leading to chemotherapy induced peripheral neuropathy (CIPN).⁽⁵⁾ Peripheral neuropathy is a

long-standing risk factor for falls, fractures, and disability in the general population.⁽⁶⁻⁸⁾

Accordingly, CIPN in BrCa survivors is strongly associated with decreased mobility, increased falls, and increased disability.^(9,10) Further, BrCa survivors with CIPN may reduce their physical activity due to their enhanced fall risk (e.g., fear of falling) and altered gait patterns,⁽¹¹⁾ which would reduce weight bearing exercise and further contribute to bone fragility beyond fall risk alone. However, whether CIPN is a risk factor for NTFx among BrCa survivors has not been investigated. Addressing this knowledge gap could assist clinicians in identifying high risk subsets of the BrCa population for adjunct osteoporosis therapies and rehabilitation, thus improving bone and overall health.

A strong focus of survivorship care has been the identification of BrCa survivors at risk for cancer treatment induced bone loss and subsequent NTFx. Currently, the guidelines from the American Society Cancer Organization (ASCO) and European Society for Medical Oncology (ESMO) both recommend screening of BrCa survivors for cancer treatment-induced bone loss.^(12,13) It is recommended that risk factors for osteoporosis are reviewed, including aromatase inhibitor use, age, BMI, physical activity, smoking, alcohol use, and a personal or family history of hip fracture.^(12,14) However, CIPN is not among the ASCO or ESMO identified risk factors for NTFx, which is likely due to a lack of empirical evidence.⁽¹²⁾ Therefore, there is a need to determine if CIPN is a risk factor for NTFx among breast cancer survivors.

Nationwide administrative claims data provide an opportunity to examine the association between CIPN and acute NTFx risk among a large, heterogeneous population. Therefore, the purpose of this propensity score-matched, observational cohort study was to leverage claims data

to determine whether CIPN is associated with an increased one-year incidence rate of NTFx among women with BrCa. We hypothesized that women with newly diagnosed BrCa and CIPN (BrCa+/CIPN+) would have an increased one-year incidence rate of NTFx compared to women with newly diagnosed BrCa without CIPN (BrCa+/CIPN-) and women without BrCa and without CIPN (BrCa-/CIPN-).

Methods

Data source

This study used claims data from the Optum's de-identified Clinformatics® Data Mart Database. This administrative claims data source is a national single private payer and contains medical and outpatient pharmacy data from beneficiaries that are covered by commercial or Medicare Advantage health plans in the United States, as previously described.⁽¹⁵⁾ In order to be enrolled, the beneficiary either pays for insurance coverage out of pocket, is covered by their employer, or is covered by their spouse that has employer-based coverage that extends to family members. As a result, this sample may reflect a slightly more affluent sector of the general population and the findings from this study should be interpreted within the scope of this privately insured sample. Medical, procedure, and outpatient pharmacy claims from January 1, 2010 to December 31, 2014 (five full calendar years) were used in this analysis. Since data are de-identified, the University Institutional Review Board approved this study as non-regulated.

All conditions, procedures, and medications were identified using codes and generic names of medications: International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes identified all medical conditions; Current Procedural Terminology codes identified all procedures; and chemotherapy and BrCa treatment agents were

identified using the generic names of relevant medications and relevant Healthcare Common Procedure Coding System (HCPCS) codes for non-oral administered agents and are included in **Supplementary Table 1**.

Sample selection

The primary group of interest was women with newly diagnosed BrCa that developed CIPN. Both BrCa and CIPN were identified by ≥ 1 claim that contained the ICD-9-CM codes for malignant (174.x) and non-malignant (233.0) BrCa and CIPN (357.6), respectively. To identify incidence of CIPN in women with BrCa, the first claim of CIPN was identified in a three-year period from July 1, 2011 to June 30, 2014 among women with BrCa. Individuals were excluded if they had a claim for CIPN prior to the first CIPN claim from July 1, 2011 to June 30, 2014 in order to isolate incident cases. As the majority of CIPN cases have been diagnosed approximately six months from the onset of initiating chemotherapy,⁽¹⁶⁾ the index date (i.e., start date of follow-up) for the BrCa+/CIPN+ group was six months before their first CIPN claim date to better capture how chemotherapy may lead to acute risk of NTFx (i.e., 1 year).

In order to determine if the association of CIPN with one-year incidence rate of NTFx is beyond the effect of BrCa, two groups were used for comparison: women with BrCa but without CIPN (BrCa+/CIPN-) and women without BrCa and without CIPN (BrCa-/CIPN-). For the BrCa+/CIPN- group, only incident BrCa cases were included to limit confounding by the effect of a newly diagnosed condition on risk of NTFx (e.g., change in lifestyle). Further, the index date for the BrCa+/CIPN+ and BrCa+/CIPN- groups were aligned with one another based on the time course of BrCa diagnosis and treatment. Specifically, the first BrCa claim, without a preceding BrCa claim, was identified from January 1, 2011 to September 31, 2013. As

chemotherapy often starts approximately three months after the initial BrCa diagnosis,⁽¹⁷⁾ the index date for the BrCa+/CIPN- group was three months after the first BrCa claim date. For the second comparison group, BrCa-/CIPN-, women that had no claims for BrCa or CIPN and did not have exposure to chemotherapy were included, and their index date was randomly assigned in the calendar years 2011 to 2013 using a uniform distribution (visually inspected by author DGW), as previously described.⁽¹⁸⁾

Following group allocation, women were included if they were: (1) ≥ 18 years of age; (2) had ≥ 12 -months of continuous health plan enrollment in the pre-index period to ascertain baseline data, which is common practice for claims-based research;⁽¹⁹⁾ and (3) had ≥ 1 day of follow-up in the post-index period for incidence of NTFx to retain as much of the starting sample as possible given the ability of this study to account for censoring. Individuals were excluded if they had ≥ 1 fracture at any location and of any type (e.g., NTFx, trauma-related fracture) in their pre-index period, because sustaining a fracture increases risk for subsequent fracture regardless of energy level.⁽²⁰⁾

NTFx

Incidence of NTFx in the one-year post-index period was identified as a fracture that occurred at an unspecified site, vertebral column, hip (including proximal femur), non-proximal femur, tibia/fibula, humerus, or ulna/radius that did not have a trauma code (e.g., fell from roof, car accident) seven days before and after the fracture claim date, as described previously.⁽²¹⁻²⁴⁾ For those that did not sustain an NTFx in the one-year post-index period, individuals were right censored as the day they discontinued health plan enrollment or end of study period (i.e., one-year post-index), based on whichever occurred first.

Covariates

Covariates were selected based on their relevance to CIPN, BrCa, NTFx, and availability and reliability in administrative claims databases. Age, race, and U.S. region of residence from the time of index date, and whether the BrCa was malignant or non-malignant was included. Chemotherapy exposure was determined as ≥ 1 outpatient pharmacy claim for any relevant chemotherapy agents or ≥ 1 medical claim for any relevant HCPCS codes for non-oral administered chemotherapy. Chemotherapy included neurotoxic and non-neurotoxic agents⁽²⁵⁾ and are included **Supplementary Table 1**, and examined in this study as two non-mutually exclusive variables: any chemotherapy, including both neurotoxic and non-neurotoxic agents and neurotoxic agents. As guided by previous studies,^(26,27) osteoporosis medications prescribed in the pre-index period were included. Given the negative effect on skeletal health, glucocorticoid medications prescribed in the pre-index period were included. Relevant to BrCa and skeletal health, hormonal therapies were identified from the pre-index period to the day of each person's censoring date, and included selective estrogen receptor modulators (SERM; tamoxifen and fulvestrant), aromatase inhibitors (anastrozole, letrozole, exemestane), and ovarian function suppressers (goserelin acetate, leuprolide acetate, triptorelin pamoate). Raloxifene is a type of SERM often prescribed to women with BrCa for osteoporosis management, and was therefore placed in the osteoporosis group and not in the SERM group in the current study. Baseline comorbidities were identified in the 12-month pre-index period by at least one claim with an ICD-9-CM code for osteoporosis, type 2 diabetes, and renal disease (i.e., acute kidney failure, renal sclerosis, and chronic kidney disease stages 1-5, dialysis, and/or kidney transplant), as previously described.⁽²⁸⁻³¹⁾

Propensity-score matching

One-year incidence of NTFx is a rare event and may limit the interpretability of covariate adjusted regression models, especially for observational study designs. Therefore, to account for confounders that may influence the associations of interest without the need for adjustment of several covariates, the two comparison groups (i.e., BrCa+/CIPN-, BrCa-/CIPN-) were each matched to the primary group of interest, BrCa+/CIPN+, using a propensity score computed by the PSMATCH procedure in SAS version 9.4 (SAS Institute, Cary, NC, USA). The greedy nearest neighbor method was used after randomizing the order of the comparator groups. Given the small sample size and rare outcome, the goal of the matching ratio of 1:x (case:control) was to maximize the number of comparators per case to increase confidence in the analyses using a standard caliper of no more than 0.50, without losing any participants from the BrCa+/CIPN+ group to limit bias, while achieving success in balanced matching. For both comparison groups, age, race, U.S. region of residence, osteoporosis, glucocorticoid medication use, and all comorbidities were initially considered to create the propensity score. For the BrCa+/CIPN- comparison group, cancer-related variables were additionally considered to initially create the propensity score, including whether the BrCa was malignant, exposure to chemotherapy agents, and exposure to hormonal therapy (i.e., SERM, aromatase inhibitors, ovarian function suppressors). Balance in matching was examined and if not met, alternative approaches were taken (discussed below).

Statistical analysis

Descriptive characteristics were summarized for each group and compared using the Chi-Squared test for categorical variables or the independent t-test for continuous variables to ensure balance in matching. The crude incidence rate (IR) and 95% confidence interval (CI) of any NTFx was estimated for each group as the number of NTFx events divided by the amount of person-years and expressed as per 100 per year. The crude IR ratio (IRR) and 95% CI⁽³²⁾ of any NTFx was estimated for the BrCa+/CIPN+ group and compared to BrCa+/CIPN-, and BrCa-/CIPN- separately. There were too few NTFx events in the primary group of interest to examine site-specific effects.

Sensitivity analysis

If relevant covariates were unable to achieve balance in matching or were statistically significantly different between groups, Cox proportional hazards regression was used to adjust for those covariates by estimating the HR (with 95% CI), with the interpretation focused on the main effect of group (i.e., BrCa+/CIPN+ vs. comparison group). These analyses were performed to determine if any unbalance in covariates impacted the association between group and incidence of any NTFx in the primary analysis.

Due to the observational design, results are subject to bias due to unmeasured confounding. To assess the magnitude of unmeasured confounding, the e-value (with 95% CI) for the association between group and incidence of any NTFx was estimated. An e-value measures the minimum strength of association needed to explain away an association between the exposure (group) and outcome (incidence of any NTFx).⁽³³⁾

Analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA) and $P < 0.05$ was considered statistically significant.

Results

Balanced matching without omitting any participant from the BrCa+/CIPN+ group was not possible for BrCa+/CIPN- when malignant BrCa was included or when SERM, aromatase inhibitors, and ovarian function suppressors were included as separate variables. After omitting malignant BrCa and creating a single binary variable (yes vs. no) for SERM, aromatase inhibitors, and/or ovarian function suppressors, successful matching was achieved. For both comparison groups, the matching ratio was 1:11 (case:control). Descriptive characteristics of women with BrCa+/CIPN+ (n=359) and their matched comparison groups, BrCa+/CIPN- (n=3,949), and BrCa-/CIPN- (n=3,949) is presented in **Table 1**. Using the Chi-square test, the prevalence of malignant BrCa was significantly lower ($P<0.001$) and the prevalence of aromatase inhibitors was significantly higher ($P=0.033$) for BrCa+/CIPN+ as compared to BrCa+/CIPN-; no other group differences were observed.

The mean (standard deviation) follow-up time in days was similar among the three groups and was 356-362 (29-39) days. Only one participant (BrCa+/CIPN+) from the full sample was right censored due to a drop in health plan enrollment. The crude IR and IRR of any NTFx is presented in **Table 2**. The crude IR (95% CI) was 4.54 (2.32-6.77) for BrCa+/CIPN+, 2.53 (2.03-3.04) for BrCa+/CIPN-, and 1.76 (1.35-2.18) for BrCa-/CIPN-. The crude IRR was significantly elevated for BrCa+/CIPN+ as compared to BrCa+/CIPN- (IRR=1.80; 95% CI=1.06-3.05) and BrCa-/CIPN- (IRR=2.58; 95% CI=1.50-4.44).

Sensitivity analysis

The HR of NTFx incidence before and after adjusting for covariates that were significantly different between BrCa+/CIPN+ and BrCa+/CIPN- is presented in **Table 3**. There were too few NTFx events to adjust for malignant BrCa. The HR remained unchanged after adjusting for aromatase inhibitors (HR=1.79; 95% CI=1.06-3.04).

The e-value (lower 95% CI) that would be needed to fully explain away the effect of BrCa+/CIPN+ compared to BrCa+/CIPN- and BrCa-/CIPN- was 3.00 (1.31) and 4.60 (2.37), respectively.

Discussion

The main finding from this study suggests that CIPN is an independent risk factor for one-year NTFx incidence rate in BrCa survivors. More specifically, women with BrCa and CIPN exhibit an increased one-year incidence rate of NTFx compared to women with BrCa but without CIPN and women with neither. Importantly, BrCa survivors with CIPN continued to demonstrate a higher one-year NTFx incidence rate compared to BrCa survivors without CIPN after adjustment for aromatase inhibitor use. Collectively, our study provides evidence that CIPN may be an unrecognized risk factor for NTFx in BrCa survivors, a finding which may help to inform clinicians and guidelines aimed at optimizing bone health and fall prevention in BrCa survivors.

Prior research investigating the association between CIPN and NTFx risk in BrCa survivors is rare. However, chemotherapy has been associated with decreased bone density with the greatest evidence coming from premenopausal survivors,⁽³⁴⁾ where the chemotherapy treatment induces menopause and, thereby, increases bone resorption through diminished estrogen signaling.⁽³⁵⁾ In

the current study, we have accounted for chemotherapy exposure between BrCa+/CIPN+ and BrCa+/CIPN- with our propensity matching study design and the median age of survivors in our study is 61, which is well over the median age of menopause at 51.⁽³⁶⁾

The mechanism(s) by which CIPN may contribute to NTFx risk are unknown. However, potential mechanisms may stem from direct and indirect effects on bone mass and architecture in addition to increasing the rate of falls. Bone metabolism and specifically bone resorption can be influenced by pro-inflammatory cytokines, which are known to be increased in CIPN⁽³⁷⁾, and may cause decrements in bone quality.⁽³⁸⁾ It is proposed that extracellular matrix (ECM) protein dephosphorylation occurs with bone resorption and may contribute to fragility fractures.⁽³⁹⁾ Osteopontin (OPN) is a non-collagenous protein that is abundant in the ECM of bone and whose degree of phosphorylation can influence both bone mineralization⁽⁴⁰⁾ and the mechanical dissipation of bone impact force.^(39,41) Interestingly, serum OPN levels have been found to be associated with the development of CIPN⁽⁴²⁾ and separately with increased osteoporotic changes in postmenopausal women.⁽⁴³⁾ Further research is needed to determine if ECM bone proteins, including OPN, play a role in NTFx risk among individuals with CIPN.

CIPN may also negatively influence bone mass and architecture indirectly through reductions in physical activity. Physical activity, including walking, may be decreased due to neuropathic pain or fear of falling. Adequate physical activity is known to be necessary for maintaining BMD⁽⁴⁴⁾ and preventing sarcopenia,⁽⁴⁵⁾ but also because it has been independently associated with a lower risk for total fractures.⁽⁴⁶⁾ Furthermore, alterations in the response to perturbation (e.g. slips and trips) in the setting of suboptimal neuromuscular function from CIPN may cause abnormal bone

loading and lead to microscopic cracks in the cortical bony architecture⁽⁴⁷⁾ thereby increasing the susceptibility to an eventual NTFx.^(48,49)

Falls biomechanically challenge the fracture resistance capability of bone and may increase risk for NTFx.⁽⁵⁰⁾ One model of falls⁽⁵¹⁾ suggests that falls result due to an inability to successfully respond to perturbation which is a function of both neuromuscular⁽⁵²⁾ and neurocognitive⁽⁵³⁾ capacities. Previous research has demonstrated CIPN's neuromuscular dysfunction including changes in sensation, postural instability,⁽⁵⁴⁾ and strength⁽⁵⁵⁾ cause gait impairments in BrCa survivors⁽¹¹⁾ and lead to falls.^(10,56) Recently, depression⁽⁵⁷⁾ and anxiety⁽⁵⁸⁾, known fall risk factors, have been associated with BrCa survivors with CIPN.⁽⁵⁹⁾ Moreover, alterations in neurocognitive function impact gait impairments⁽⁶⁰⁾ among BrCa survivors with CIPN and likely contribute to increased fall risk in this vulnerable population.

Our study is not without limitations and many are secondary to the use of claims data, which is dependent on patients reporting their symptoms and providers selecting the proper codes for diagnoses, medications, and procedures. Therefore, the prevalence of CIPN, chemotherapeutic use, and other medication use are likely underrepresented approximations. Due to a likely underrepresentation of chemotherapeutic use and use of an ICD-9 code, we are unable to determine if the peripheral neuropathy is truly due to chemotherapy. However, it has been shown that claims data shows high specificity for CIPN.⁽⁶¹⁾ Due to lack of imaging correlation of the fractures and survivor's history of cancer we are unable to completely attribute the fractures to insufficiency and not to metastasis or trauma. Our study is also limited as claims data do not contain information on physical activity, BMD, FRAX score, or BMI, which are all known

variables impacting NTFx risk in breast cancer survivors. Lastly, this study included fractures without evidence of trauma. Previous studies have found that individuals with low BMD also sustain a higher rate of high-trauma fractures.^(62,63) Future studies are needed to determine if CIPN is associated with high-trauma fractures.

These limitations notwithstanding, our findings may have clinical implications. Specifically, we have identified CIPN as a novel risk factor in BrCa survivors for NTFx, independent of aromatase inhibitor use. Currently, guidelines use BMD, evaluated by DEXA scan, to clinically evaluate risk of NTFx and prescription of bone modifying agents. Despite added benefit, the use of BMD does not always identify at risk populations, including BrCa survivors who suffer fractures at a higher BMD than women with postmenopausal osteoporosis.⁽⁶⁴⁾ Given the morbidity and mortality associated with NTFx, it is essential to identify BrCa survivors at risk for NTFx. If other studies confirm CIPN to be a risk factor for NTFx, then its addition to the ASCO and ESMO guidelines for bone health in BrCa survivors may be warranted.

In summary, our study provides evidence that CIPN is an independent risk factor for NTFx in BrCa survivors. Moving forward, research should focus on validating the association of CIPN with NTFx as it may inform future clinical decision making and future guidelines aimed at managing bone fragility in BrCa survivors. Future research is necessary to elucidate the precise mechanism(s) responsible for the association we found between CIPN and NTFx. Overall, BrCa survivors with CIPN may benefit from rehabilitative interventions which mitigate their fall risk and optimize their bone health.

References

1. American Cancer Society. Cancer Treatment & Survivorship Facts & Figures 2016-2017. Am. Cancer Soc. 2016;
2. Guise TA. Bone Loss and Fracture Risk Associated with Cancer Therapy. *Oncologist*. 2006;11(10):1121–31.
3. Garg A, Leitzel K, Ali S, Lipton A. Antiresorptive Therapy in the Management of Cancer Treatment-Induced Bone Loss. *Curr. Osteoporos. Rep.* 2015;13(2):73–7.
4. Colzani E, Clements M, Johansson AL V, Liljegren A, He W, Brand J, Adolfsson J, Fornander T, Hall P, Czene K. Risk of hospitalisation and death due to bone fractures after breast cancer: a registry-based cohort study. *Br. J. Cancer* [Internet]. Nature Publishing Group; 2016 Nov 4;115(11):1400–7. Available from: <http://www.nature.com/articles/bjc2016314>
5. Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. *Pain* [Internet]. 2014 Dec;155(12):2461–70. Available from: <http://journals.lww.com/00006396-201412000-00006>
6. Richardson JK, Hurvitz EA. Peripheral Neuropathy: A True Risk Factor for Falls. *Journals Gerontol. Ser. A Biol. Sci. Med. Sci.* [Internet]. 1995 Jul 1;50A(4):M211–5. Available from: <https://academic.oup.com/biomedgerontology/article-lookup/doi/10.1093/gerona/50A.4.M211>
7. Karvonen-Gutierrez CA, Ylitalo KR. Prevalence and Correlates of Disability in a Late Middle-Aged Population of Women. *J. Aging Health* [Internet]. 2013 Jun 15;25(4):701–17. Available from: <http://journals.sagepub.com/doi/10.1177/0898264313488165>

8. Rasmussen NH, Dal J. Falls and Fractures in Diabetes—More than Bone Fragility. *Curr. Osteoporos. Rep.* [Internet]. *Current Osteoporosis Reports*; 2019 Jun 26;17(3):147–56. Available from: <http://link.springer.com/10.1007/s11914-019-00513-1>
9. Kolb NA, Smith AG, Singleton JR, Beck SL, Stoddard GJ, Brown S, Mooney K. The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling. *JAMA Neurol.* [Internet]. 2016 Jul 1;73(7):860. Available from: <http://archneur.jamanetwork.com/article.aspx?doi=10.1001/jamaneurol.2016.0383>
10. Winters-Stone KM, Horak F, Jacobs PG, Trubowitz P, Dieckmann NF, Stoyles S, Faithfull S. Falls, Functioning, and Disability Among Women With Persistent Symptoms of Chemotherapy-Induced Peripheral Neuropathy. *J. Clin. Oncol.* [Internet]. 2017;35(23):2604–12. Available from: <http://ascopubs.org/doi/10.1200/JCO.2016.71.3552><http://www.ncbi.nlm.nih.gov/pubmed/28586243><http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5549452>
11. Monfort SM, Pan X, Patrick R, Ramaswamy B, Wesolowski R, Naughton MJ, Loprinzi CL, Chaudhari AMW, Lustberg MB. Gait, balance, and patient-reported outcomes during taxane-based chemotherapy in early-stage breast cancer patients. *Breast Cancer Res. Treat.* Springer US; 2017;164(1):69–77.
12. Shapiro CL, Van Poznak C, Lacchetti C, Kirshner J, Eastell R, Gagel R, Smith S, Edwards BJ, Frank E, Lyman GH, Smith MR, Mhaskar R, Henderson T, Neuner J. Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline. *J. Clin. Oncol.* [Internet]. 2019 Nov 1;37(31):2916–46. Available from: <https://ascopubs.org/doi/10.1200/JCO.19.01696>

13. Coleman R, Body JJ, Aapro M, Hadji P, Herrstedt J. Bone health in cancer patients: ESMO clinical practice guidelines. *Ann. Oncol.* [Internet]. Elsevier Masson SAS; 2014;25(April):124–37. Available from: <http://dx.doi.org/10.1093/annonc/mdu103>
14. Hadji P, Coleman RE, Wilson C, Powles TJ, Clézardin P, Aapro M, Costa L, Body J-J, Markopoulos C, Santini D, Diel I, Di Leo A, Cameron D, Dodwell D, Smith I, Gnant M, Gray R, Harbeck N, Thurlimann B, Untch M, Cortes J, Martin M, Albert U-S, Conte P-F, Ejlertsen B, Bergh J, Kaufmann M, Holen I. Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. *Ann. Oncol.* [Internet]. Elsevier Masson SAS; 2016 Mar;27(3):379–90. Available from: <http://dx.doi.org/10.1093/annonc/mdv617>
15. Whitney D, Kamdar N, Hirth RA, Hurvitz EA, Peterson MD. Economic burden of paediatric-onset disabilities among young and middle-aged adults in the USA: a cohort study of privately insured beneficiaries. *BMJ Open* [Internet]. 2019 Sep 3;9(9):e030490. Available from: <http://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2019-030490>
16. Pereira S, Fontes F, Sonin T, Dias T, Fragoso M, Castro-Lopes JM, Lunet N. Neurological complications of breast cancer: A prospective cohort study. *Breast* [Internet]. 2015 Oct;24(5):582–7. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26096894>
17. Kupstas AR, Hoskin TL, Day CN, Habermann EB, Boughey JC. Effect of Surgery Type on Time to Adjuvant Chemotherapy and Impact of Delay on Breast Cancer Survival: A National Cancer Database Analysis. *Ann. Surg. Oncol.* [Internet]. 2019 Oct 22;26(10):3240–9. Available from: <http://link.springer.com/10.1245/s10434-019-07566-7>
18. Whitney DG, Bell S, Etter JP, Prisby RD. The cardiovascular disease burden of non-traumatic fractures for adults with and without cerebral palsy. *Bone* [Internet]. 2020

Jul;136:115376. Available from:

<https://linkinghub.elsevier.com/retrieve/pii/S8756328220301563>

19. Chang H-Y, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted Diabetes Complications Severity Index in claims data. *Am. J. Manag. Care* [Internet]. 2012;18(11):721–6. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23198714>
20. Holloway KL, Brennan SL, Kotowicz MA, Bucki-Smith G, Timney EN, Dobbins AG, Williams LJ, Pasco JA. Prior fracture as a risk factor for future fracture in an Australian cohort. *Osteoporos. Int.* 2014;26(2):629–35.
21. Whitney DG, Whibley D, Jepsen KJ. The effect of low-trauma fracture on one-year mortality rate among privately insured adults with and without neurodevelopmental disabilities. *Bone* [Internet]. Elsevier; 2019;129(September):115060. Available from: <https://doi.org/10.1016/j.bone.2019.115060>
22. Whitney DG, Whitney RT, Prisby RD, Jepsen KJ. Low-Trauma Fracture Increases 12-Month Incidence of Cardiovascular Disease for Adults With Cerebral Palsy. *J. Orthop. Res.* [Internet]. John Wiley & Sons, Ltd; 2020;38(4):803–10. Available from: <http://dx.doi.org/10.1002/jor.24515>
23. Whitney DG, Bell S, McNamara NA, Hurvitz EA. The mortality burden attributable to nontrauma fracture for privately insured adults with epilepsy. *Epilepsia.* 2020;61(4):714–24.
24. Whitney DG. Nontrauma fracture increases risk for respiratory disease among adults with cerebral palsy. *J. Orthop. Res.* 2020;38(12):2551–8.
25. Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. *Nat. Rev. Neurol.* [Internet]. 2010 Dec 9;6(12):657–66. Available from:

<http://www.nature.com/articles/nrneuro1.2010.160>

26. Keshishian A, Boytsov N, Burge R, Krohn K, Lombard L, Zhang X, Xie L, Baser O. Examining the effect of medication adherence on risk of subsequent fracture among women with a fragility fracture in the U.S. medicare population. *J. Manag. Care Spec. Pharm.* 2017;
27. Liu J, Guo H, Rai P, Pinto L, Barron R. Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis. *Osteoporos. Int.* 2018;
28. Whitney DG, Warschausky SA, Whibley D, Kratz A, Murphy SL, Hurvitz EA, Peterson MD. Clinical factors associated with mood affective disorders among adults with cerebral palsy. *Neurol. Clin. Pract.* [Internet]. 2020 Jun;10(3):206–13. Available from: <http://cp.neurology.org/lookup/doi/10.1212/CPJ.0000000000000721>
29. Whitney DG. Prevalence of High-Burden Medical Conditions Among Young and Middle-Aged Adults With Pediatric-Onset Medical Conditions: Findings From US Private and Public Administrative Claims Data. *Int. J. Heal. Policy Manag.* [Internet]. 2019 Jul 29;8(11):629–35. Available from: http://www.ijhpm.com/article_3651.html
30. Whitney DG, Kamdar NS, Ng S, Hurvitz EA, Peterson MD. Prevalence of high-burden medical conditions and health care resource utilization and costs among adults with cerebral palsy. *Clin. Epidemiol.* [Internet]. 2019 Jun;Volume 11:469–81. Available from: <https://www.dovepress.com/prevalence-of-high-burden-medical-conditions-and-health-care-resource--peer-reviewed-article-CLEP>
31. Whitney DG, Schmidt M, Bell S, Morgenstern H, Hirth RA. Incidence rate of advanced chronic kidney disease among privately insured adults with neurodevelopmental disabilities. *Clin. Epidemiol.* 2020;12:235–43.

32. Rothman S. *Modern epidemiology*. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2008.
33. VanderWeele TJ, Ding P. Sensitivity Analysis in Observational Research: Introducing the E-Value. *Ann. Intern. Med.* [Internet]. 2017 Aug 15;167(4):268. Available from: <http://annals.org/article.aspx?doi=10.7326/M16-2607>
34. Monroy-Cisneros K, Esparza-Romero J, Valencia ME, Guevara-Torres AG, Méndez-Estrada RO, Anduro-Corona I, Astiazarán-García H. Antineoplastic treatment effect on bone mineral density in Mexican breast cancer patients. *BMC Cancer*. 2016;16(1):1–7.
35. Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Snowdon CF, Hall E, Bliss JM, Coombes RC. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. *Lancet Oncol.* [Internet]. 2007 Feb;8(2):119–27. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S1470204507700037>
36. Crawford SL, Casey VA, Avis NE, McKinlay SM. A Longitudinal Study of Weight and the Menopause Transition. *Menopause* [Internet]. 2000;7(2):96–104. Available from: <http://journals.lww.com/00042192-200007020-00005>
37. Wang X-M, Lehky TJ, Brell JM, Dorsey SG. Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. *Cytokine* [Internet]. Elsevier Ltd; 2012 Jul;59(1):3–9. Available from: <http://dx.doi.org/10.1016/j.cyto.2012.03.027>
38. D'Oronzo S, Stucci S, Tucci M, Silvestris F. Cancer treatment-induced bone loss (CTIBL): Pathogenesis and clinical implications. *Cancer Treat. Rev.* [Internet]. Elsevier Ltd; 2015 Nov;41(9):798–808. Available from:

<http://dx.doi.org/10.1016/j.ctrv.2015.09.003>

39. Sroga GE, Vashishth D. Phosphorylation of Extracellular Bone Matrix Proteins and Its Contribution to Bone Fragility. *J. Bone Miner. Res.* 2018;33(12):2214–29.
40. Boskey AL. Noncollagenous matrix proteins and their role in mineralization. *Bone Miner.* [Internet]. 1989 May;6(2):111–23. Available from:
<https://linkinghub.elsevier.com/retrieve/pii/0169600989900445>
41. Fantner GE, Adams J, Turner P, Thurner PJ, Fisher LW, Hansma PK. Nanoscale Ion Mediated Networks in Bone: Osteopontin Can Repeatedly Dissipate Large Amounts of Energy. *Nano Lett.* [Internet]. 2007 Aug;7(8):2491–8. Available from:
<https://pubs.acs.org/doi/10.1021/nl0712769>
42. Pizzamiglio C, Ripellino P, Prandi P, Clemente N, Saggia C, Rossi V, Strigaro G, Luigi Foglio Bonda P, Comi C, Cantello R. Nerve conduction, circulating osteopontin and taxane-induced neuropathy in breast cancer patients. *Neurophysiol. Clin.* [Internet]. Elsevier Masson SAS; 2020 Feb;50(1):47–54. Available from:
<https://doi.org/10.1016/j.neucli.2019.12.001>
43. Fodor D, Bondor C, Albu A, Simon SP, Craciun A, Muntean L. The value of osteopontin in the assessment of bone mineral density status in postmenopausal women. *J. Investig. Med.* 2013;61(1):15–21.
44. Feskanich D, Willett W, Colditz G. Walking and leisure-time activity and risk of hip fracture in postmenopausal women. *J. Am. Med. Assoc.* 2002;288(18):2300–6.
45. Beaudart C, Dawson A, Shaw SC, Harvey NC, Kanis JA, Binkley N, Reginster JY, Chapurlat R, Chan DC, Bruyère O, Rizzoli R, Cooper C, Dennison EM, Adib G, Brandi ML, Chevalley T, Clark P, Dawson-Hughes B, El Maghraoui A, Engelke K, Fielding R,

- Foldes AJ, Gugliemi G, Kaufman JM, Larijani B, Lems W, van Loon LJC, Lyritis GP, Maggi S, Masi L, McCloskey E, Messina OD, Papaioannou A, Szulc P, Veronese N. Nutrition and physical activity in the prevention and treatment of sarcopenia: systematic review. *Osteoporos. Int.* 2017.
46. LaMonte MJ, Wactawski-Wende J, Larson JC, Mai X, Robbins JA, LeBoff MS, Chen Z, Jackson RD, LaCroix AZ, Ockene JK, Hovey KM, Cauley JA. Association of Physical Activity and Fracture Risk Among Postmenopausal Women. *JAMA Netw. Open* [Internet]. 2019 Oct 25;2(10):e1914084. Available from: <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2753526>
47. Tamim Diab, Deepak Vashishth. Morphology, Localization and Accumulation of in Vivo Microdamage in Human Cortical Bone. *Bone* [Internet]. 2007;23(1):1–7. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3624763/pdf/nihms412728.pdf>
48. Burr DB, Turner CH, Naick P, Forwood MR, Ambrosius W, Sayeed Hasan M, Pidaparti R. Does microdamage accumulation affect the mechanical properties of bone? *J. Biomech.* [Internet]. 1998 Apr;31(4):337–45. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0021929098000165>
49. Vashishth D. Rising crack-growth-resistance behavior in cortical bone: *J. Biomech.* [Internet]. 2004 Jun;37(6):943–6. Available from: <https://linkinghub.elsevier.com/retrieve/pii/S0021929003004044>
50. Schwartz A V, Nevitt MC, Brown BW, Kelsey JL. Increased falling as a risk factor for fracture among older women: the study of osteoporotic fractures. *Am. J. Epidemiol.* [Internet]. 2005 Jan 15;161(2):180–5. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/15632268>

51. Richardson JK. Imbalanced. *Am. J. Phys. Med. Rehabil.* [Internet]. 2017 Jan;96(1):55–9. Available from: <http://journals.lww.com/00002060-201701000-00008>
52. Richardson JK, Demott T, Allet L, Kim H, Ashton-miller JA. Hip strength: Ankle proprioceptive threshold ratio predicts falls and injury in diabetic neuropathy. *Muscle and Nerve.* 2014;
53. Richardson JK, Eckner JT, Allet L, Kim H, Ashton-Miller JA. Complex and Simple Clinical Reaction Times Are Associated with Gait, Balance, and Major Fall Injury in Older Subjects with Diabetic Peripheral Neuropathy. *Am. J. Phys. Med. Rehabil.* 2017;
54. McCrary JM, Goldstein D, Trinh T, Timmins HC, Li T, Menant J, Friedlander M, Lewis CR, Hertzberg M, O’Neill S, King T, Bosco A, Harrison M, Park SB. Balance deficits and functional disability in cancer survivors exposed to neurotoxic cancer treatments. *JNCCN J. Natl. Compr. Cancer Netw.* 2019;17(8):949–55.
55. Gewandter JS, Fan L, Magnuson A, Mustian K, Peppone L, Heckler C, Hopkins J, Tejani M, Morrow GR, Mohile SG. Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study. *Support. Care Cancer* [Internet]. 2013 Jul 28;21(7):2059–66. Available from: <http://link.springer.com/10.1007/s00520-013-1766-y>
56. Kolb NA, Smith AG, Singleton JR, Beck SL, Stoddard GJ, Brown S, Mooney K. The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling. *JAMA Neurol.* 2016;73(7):860–6.
57. Kvelde T, Lord SR, Close JCT, Reppermund S, Kochan NA, Sachdev P, Brodaty H, Delbaere K. Depressive symptoms increase fall risk in older people, independent of antidepressant use, and reduced executive and physical functioning. *Arch. Gerontol.*

Geriatr. [Internet]. Elsevier Ireland Ltd; 2015 Jan;60(1):190–5. Available from:
<http://dx.doi.org/10.1016/j.archger.2014.09.003>

58. Sturnieks DL, Delbaere K, Brodie MA, Lord SR. The influence of age, anxiety and concern about falling on postural sway when standing at an elevated level. *Hum. Mov. Sci.* [Internet]. Elsevier B.V.; 2016 Oct;49:206–15. Available from:
<http://dx.doi.org/10.1016/j.humov.2016.06.014>
59. McNeish, Brendan L; Richardson, James K; Whitney DG. Chemotherapy induced peripheral neuropathy onset increases the early risk for depression and anxiety in breast cancer survivors. *Submiss.* 2020;
60. Monfort SM, Pan X, Loprinzi CL, Lustberg MB, Chaudhari AMW. Exploring the Roles of Central and Peripheral Nervous System Function in Gait Stability: Preliminary Insights from Cancer Survivors. *Gait Posture* [Internet]. 2019 Jun;71:62–8. Available from:
<https://linkinghub.elsevier.com/retrieve/pii/S0966636218316382>
61. Gewandter JS, Kleckner AS, Marshall JH, Brown JS, Curtis LH, Bautista J, Dworkin RH, Kleckner IR, Kolb N, Mohile SG, Mustian KM. Chemotherapy-induced peripheral neuropathy (CIPN) and its treatment: an NIH Collaboratory study of claims data. *Support. Care Cancer. Supportive Care in Cancer*; 2020;28(6):2553–62.
62. Mackey DC. High-Trauma Fractures and Low Bone Mineral Density in Older Women and Men. *JAMA* [Internet]. 2007 Nov 28;298(20):2381. Available from:
<http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.298.20.2381>
63. Leslie WD, Schousboe JT, Morin SN, Martineau P, Lix LM, Johansson H, McCloskey E V., Harvey NC, Kanis JA. Fracture risk following high-trauma versus low-trauma fracture: a registry-based cohort study. *Osteoporos. Int.* [Internet]. Osteoporosis

International; 2020 Jun 16;31(6):1059–67. Available from:

<http://link.springer.com/10.1007/s00198-019-05274-2>

64. Edwards BJ, Gradishar WJ, Smith ME, Pacheco JA, Holbrook J, McKoy JM, Nardone B, Tica S, Godinez-Puig V, Rademaker AW, Helenowski IB, Bunta AD, Stern PH, Rosen ST, West DP, Guise TA. Elevated incidence of fractures in women with invasive breast cancer. *Osteoporos. Int.* [Internet]. 2016 Feb 21;27(2):499–507. Available from: <http://link.springer.com/10.1007/s00198-015-3246-3>

Table 1. Descriptive characteristics of propensity score matched women with (+) or without (-) breast cancer (BrCa) and chemotherapy-induced peripheral neuropathy (CIPN).

	BrCa+/CIPN+ (n=359)	BrCa+/CIPN- (n=3,949)	BrCa-/CIPN- (n=3,949)
	% (n)	% (n)	% (n)
Age, mean (SD)	61.3 (12.1)	61.3 (12.9)	61.7 (12.0)
18-40 years	4.2 (15)	4.9 (193)	3.9 (152)
41-64 years	56.8 (204)	54.9 (2,167)	56.1 (2,217)
≥65 years	39.0 (140)	40.2 (1,589)	40.0 (1,580)
Race			
White	69.9 (251)	71.6 (2,828)	71.1 (2,807)
Black	7.5 (27)	6.4 (254)	7.3 (287)
Hispanic	6.7 (24)	7.4 (292)	7.1 (282)
Asian	3.3 (12)	2.9 (116)	2.6 (101)
Other/unknown	12.5 (45)	11.6 (459)	12.0 (472)
U.S. region of residence			
West	32.6 (117)	32.4 (1,280)	30.4 (1,200)
Midwest	24.5 (88)	21.6 (854)	24.6 (972)
South	34.8 (125)	38.3 (1,511)	32.2 (1,271)
Northeast	8.1 (29)	7.7 (304)	12.8 (506)
Malignant BrCa	71.9 (258) ¹	96.6 (3,814)	0 (0)
Chemotherapy			
Any chemotherapy ⁴	43.2 (155)	42.9 (1,692)	0 (0)
Neurotoxic chemotherapy agents	38.7 (139)	36.5 (1,442)	0 (0)
Comorbidities			
Osteoporosis	8.6 (31)	7.0 (278)	7.0 (278)
Type 2 diabetes	18.7 (67)	17.2 (681)	18.1 (714)
Renal disease	5.9 (21)	4.9 (195)	5.1 (201)
Medication and hormonal therapy			
Osteoporosis medications ²	7.8 (28)	7.3 (289)	6.6 (261)
Glucocorticoid medications	18.1 (65)	19.6 (772)	18.8 (743)
Selective estrogen receptor modulators ²	13.7 (49)	16.6 (654)	0 (0)
Aromatase inhibitors	34.0 (122) ¹	28.6 (1,131)	0 (0)
Ovarian function suppression ³		0.7 (26)	0 (0)

¹ $p < 0.05$ compared to BrCa+/CIPN-.²Raloxifene is included in the osteoporosis medication group and not the selective estrogen receptor modulators group.³ $n \leq 10$ events and not reported to maintain patient de-identification and group comparisons not performed.⁴Any chemotherapy includes non-neurotoxic and neurotoxic chemotherapy agents

Table 2. Incidence rate (IR) and IR ratio (IRR) of non-trauma fracture (NTFx) for women with (+) or without (-) breast cancer (BrCa) and chemotherapy-induced peripheral neuropathy (CIPN).

	NTFx cases	Person years	Crude IR	Crude IRR	Crude IRR
	N	Years	N per 100/years (95% CI)	IRR (95% CI)	IRR (95% CI)
BrCa+/CIPN+	16	352	4.54 (2.32, 6.77)	1.80 (1.06, 3.05)	2.58 (1.50, 4.44)
BrCa+/CIPN-	99	3,903	2.53 (2.03, 3.04)	Reference	
BrCa-/CIPN-	69	3,912	1.76 (1.35, 2.18)		Reference

CI, confidence interval.

Table 3. Adjusted hazard ratio of non-trauma fracture (NTFx) for women with (+) or without (-) breast cancer (BrCa) and chemotherapy-induced peripheral neuropathy (CIPN).

	Unadjusted	Model 1
	HR (95% CI)	HR (95% CI)
BrCa+/CIPN+	1.79 (1.06, 3.04)	1.79 (1.06, 3.04)
BrCa+/CIPN-	Reference	Reference

CI, confidence interval. Model 1 adjusted for aromatase inhibitors.